Did MEI/Kyowa Kirin Beat The PI3K Tolerability Trap?
Zandelisib Shows Unexpectedly Positive Data
PI3K-delta inhibitors have often suffered from safety and tolerability issues, but Phase II data show higher efficacy and lower discontinuation rates for zandelisib than others in the class.
You may also be interested in...
Incyte’s Jakafi Flunks In Phase III Myelofibrosis Study As Loss Of Exclusivity Nears
The company said it would discontinue the Phase III LIMBER-304 trial in patients who had inadequate response to Jakafi when an analysis indicated the study would not reach its primary endpoint.
MEI/Kyowa Kirin Show More Data Supporting Zandelisib’s Safety Profile
Presentations at EHA show the drug has a favorable safety profile compared with other PI3K-delta inhibitors alone and in combination with Rituxan, plus strong efficacy.
Despite FDA Setback, MEI’s Zandelisib Could Still Break PI3K Curse
MEI/Kyowa Kirin will no longer seek accelerated approval based on a single-arm study as the FDA is calling for Phase III data due to growing conservatism regarding the PI3K class.